149 related articles for article (PubMed ID: 37755427)
1. Antiretroviral therapy intensification for HIV-associated neurocognitive disorder?
Brew BJ; Clifford DB
AIDS; 2023 Nov; 37(13):2095-2096. PubMed ID: 37755427
[No Abstract] [Full Text] [Related]
2. Improvement of HIV-associated neurocognitive disorders after antiretroviral therapy intensification: the Neuro+3 study.
Force G; Ghout I; Ropers J; Carcelain G; Marigot-Outtandy D; Hahn V; Darchy N; Defferriere H; Bouaziz-Amar E; Carlier R; Dorgham K; Callebert J; Peytavin G; Delaugerre C; de Truchis P;
J Antimicrob Chemother; 2021 Feb; 76(3):743-752. PubMed ID: 33179033
[TBL] [Abstract][Full Text] [Related]
3. Therapy recommendations for HIV-associated neurocognitive disorders.
Zirulnik JL
JAMA; 2008 Dec; 300(21):2482; author reply 2482-3. PubMed ID: 19050186
[No Abstract] [Full Text] [Related]
4. Is the use of the QPC cognitive complaints questionnaire relevant for the screening strategy of HIV-Associated neurocognitive disorders?
Zaegel-Faucher O; Laroche H; Tixier M; Morisseau V; Obry-Roguet V; Poizot-Martin I
AIDS Care; 2021 Mar; 33(3):389-397. PubMed ID: 32279542
[TBL] [Abstract][Full Text] [Related]
5. AIDS-associated mild neurocognitive impairment is delayed in the era of highly active antiretroviral therapy.
Deutsch R; Ellis RJ; McCutchan JA; Marcotte TD; Letendre S; Grant I;
AIDS; 2001 Sep; 15(14):1898-9. PubMed ID: 11579260
[No Abstract] [Full Text] [Related]
6. HIV-associated neurocognitive disorders (HAND).
Elbirt D; Mahlab-Guri K; Bezalel-Rosenberg S; Gill H; Attali M; Asher I
Isr Med Assoc J; 2015 Jan; 17(1):54-9. PubMed ID: 25739180
[TBL] [Abstract][Full Text] [Related]
7. Benefit or toxicity from neurologically targeted antiretroviral therapy?
Brew BJ
Clin Infect Dis; 2010 Mar; 50(6):930-2. PubMed ID: 20146628
[No Abstract] [Full Text] [Related]
8. HIV-associated neurocognitive disorders: perspective on management strategies.
Nabha L; Duong L; Timpone J
Drugs; 2013 Jun; 73(9):893-905. PubMed ID: 23733447
[TBL] [Abstract][Full Text] [Related]
9. CSF penetration by antiretroviral drugs.
Eisfeld C; Reichelt D; Evers S; Husstedt I
CNS Drugs; 2013 Jan; 27(1):31-55. PubMed ID: 23160938
[TBL] [Abstract][Full Text] [Related]
10. Response to "Persistence of Neuropsychologic Deficits Despite Long-Term Highly Active Antiretroviral Therapy in Patients With HIV-Related Neurocognitive Impairment".
Garvey L; Thomson EC; Main J; Winston A
J Acquir Immune Defic Syndr; 2007 Dec; 46(5):656-7, author reply 657-8. PubMed ID: 18043322
[No Abstract] [Full Text] [Related]
11. HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment.
Chan P; Brew BJ
Curr HIV/AIDS Rep; 2014 Sep; 11(3):317-24. PubMed ID: 24966139
[TBL] [Abstract][Full Text] [Related]
12. Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND).
Ndhlovu LC; Umaki T; Chew GM; Chow DC; Agsalda M; Kallianpur KJ; Paul R; Zhang G; Ho E; Hanks N; Nakamoto B; Shiramizu BT; Shikuma CM
J Neurovirol; 2014 Dec; 20(6):571-82. PubMed ID: 25227930
[TBL] [Abstract][Full Text] [Related]
13. Dramatic Improvement of MRI Abnormalities of HIV Encephalopathy after Suppressive Antiretroviral Therapy.
Dietrich DK; Laidlaw E; Hammoud DA; Pau AK; Smith BR
AIDS; 2023 Jul; 37(8):1339-1340. PubMed ID: 37771854
[No Abstract] [Full Text] [Related]
14. Effect of HIV Subtype and Antiretroviral Therapy on HIV-Associated Neurocognitive Disorder Stage in Rakai, Uganda.
Sacktor N; Saylor D; Nakigozi G; Nakasujja N; Robertson K; Grabowski MK; Kisakye A; Batte J; Mayanja R; Anok A; Gray RH; Wawer MJ
J Acquir Immune Defic Syndr; 2019 Jun; 81(2):216-223. PubMed ID: 30865184
[TBL] [Abstract][Full Text] [Related]
15. Regarding "Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors".
Biscione FM
J Acquir Immune Defic Syndr; 2007 Dec; 46(4):510; author reply 510-2. PubMed ID: 17993860
[No Abstract] [Full Text] [Related]
16. Psycho-behavioral factors associated with neurocognitive performance among people living with HIV on antiretroviral therapy in Accra, Ghana.
Asiedu N; Kretchy I; Asampong E
Afr Health Sci; 2020 Jun; 20(2):487-596. PubMed ID: 33163015
[TBL] [Abstract][Full Text] [Related]
17. CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose.
Calcagno A; Barco A; Trunfio M; Bonora S
Curr HIV/AIDS Rep; 2018 Feb; 15(1):84-91. PubMed ID: 29363025
[TBL] [Abstract][Full Text] [Related]
18. Impact of antiretroviral therapy on HIV-related brain injury.
Price RW
Clin Infect Dis; 2011 Jan; 52(2):244-7. PubMed ID: 21288851
[No Abstract] [Full Text] [Related]
19. HIV-associated dementia in the era of highly active antiretroviral therapy (HAART).
Xia C; Luo D; Yu X; Jiang S; Liu S
Microbes Infect; 2011 May; 13(5):419-25. PubMed ID: 21262373
[TBL] [Abstract][Full Text] [Related]
20. Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy.
Skinner S; Adewale AJ; DeBlock L; Gill MJ; Power C
HIV Med; 2009 Apr; 10(4):246-52. PubMed ID: 19187172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
